Metabolome Alterations Linking Sugar-Sweetened Beverage Intake with Dyslipidemia in Youth: The Exploring Perinatal Outcomes among CHildren (EPOCH) Study

Catherine C. Cohen 1,2,*, Dana Dabelea 1,2,3, Gregory Michelotti 4, Lu Tang 5, Kartik Shankar 1,2, Michael I. Goran 6 and Wei Perng 2,3,7

1 Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; dana.dabelea@cuanschutz.edu (D.D.); kartik.shankar@cuanschutz.edu (K.S.)
2 Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Denver Anschutz Medical Campus, Aurora, CO 80045, USA; wei.perng@cuanschutz.edu
3 Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
4 Metabolon, Inc., Morrisville, NC 27560, USA; gmicelotti@metabolon.com
5 Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA; lutang@pitt.edu
6 Department of Pediatrics, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA 90007, USA; goran@usc.edu
7 Department of Nutritional Sciences, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA
* Correspondence: catherine.cioffi@cuanschutz.edu

Abstract: The objective of this study was to assess intermediary metabolic alterations that link sugar-sweetened beverage (SSB) intake to cardiometabolic (CM) risk factors in youth. A total of 597 participants from the multi-ethnic, longitudinal Exploring Perinatal Outcomes among CHildren (EPOCH) Study were followed in childhood (median 10 yrs) and adolescence (median 16 yrs). We used a multi-step approach: first, mixed models were used to examine the associations of SSB intake in childhood with CM measures across childhood and adolescence, which revealed a positive association between SSB intake and fasting triglycerides (β (95% CI) for the highest vs. lowest SSB quartile: 8.1 (−0.9,17.0); p-trend = 0.057). Second, least absolute shrinkage and selection operator (LASSO) regression was used to select 180 metabolite features (out of 767 features assessed by untargeted metabolomics) that were associated with SSB intake in childhood. Finally, 13 of these SSB-associated metabolites (from step two) were also prospectively associated with triglycerides across follow-up (from step one) in the same direction as with SSB intake (Bonferroni-adj. p < 0.0003). All annotated compounds were lipids, particularly dicarboxylated fatty acids, mono- and diacylglycerols, and phospholipids. In this diverse cohort, we identified a panel of lipid metabolites that may serve as intermediary biomarkers, linking SSB intake to dyslipidemia risk in youth.

Keywords: added sugar; metabolic profiling; childhood obesity; machine learning; metabolic syndrome; hypertriglyceridemia

1. Introduction

Excess consumption of sugar-sweetened beverages (SSBs), which typically include sodas, fruit-flavored drinks, energy drinks, sports drinks, and sweetened teas/coffees, has been consistently associated with rates of overweight and obesity among youth over recent decades [1–3]. This associated weight gain may result from the energy-dense, liquid nature of SSBs, resulting in weaker satiation and compensatory food responses, or activation of the hedonic food reward system [4]. SSB intake has also been associated with cardiometabolic risk factors in childhood and adolescence, including markers of
insulin resistance, inflammation, and dyslipidemia, independent of energy intake [5–10]. Proposed mechanisms include the higher glycemic index of SSBs, which may contribute to an increased insulin secretory response [11], or associations of added sugars in SSBs, especially fructose, with hepatic de novo lipogenesis and ectopic liver fat [12–16], an effect that has been observed even when weight is held stable [13]. A critical future direction is, therefore, better understanding the pathophysiological disturbances associated with SSBs, as this may also shed light on objective biomarkers of intake of SSBs, a food group for which social norms may bias self-reported intake data.

Metabolomics is an evolving science that involves the comprehensive measurement of low molecular weight molecules, or metabolites, in biological samples. This includes endogenous compounds, which serve as products, intermediates, and substrates of chemical reactions in the human metabolism, as well as exogenous compounds, which reflect environmental exposures [17]. In adults, a study by Gibbons et al. leveraged untargeted metabolomics to identify a set of metabolites (formate, citrulline, taurine, isocitrate) that showed promise as biomarkers of SSB intake [18], though this study did not link these metabolites to any health outcomes. An alternative strategy is to evaluate the metabolome alterations linking SSB intake and cardiometabolic risk. This may be achieved by using a “meet-in-the-middle” approach [19], an analytical framework that aims to identify the functional biomarkers that mark the relationship between an exposure and a health outcome, thereby providing insight into pathophysiological alterations potentially attributable to the exposure. For example, in a cross-sectional cohort of Mexican youth, Perng et al. identified two metabolites (urate and nonanoate) that marked the relationship between SSB intake and higher blood pressure in girls [20]. While these findings serve as a foundation for understanding the link between SSB intake and one metabolic risk factor in youth, additional prospective studies are needed to further explore this pathway and establish the temporality of associations.

In this study, we investigated the intermediary metabolic alterations that mark the relationship between SSB intake in childhood and cardiometabolic risk factors measured prospectively across childhood and adolescence. This was done using data from the Exploring Perinatal Outcomes among Children (EPOCH) study, a longitudinal cohort of diverse youth, and by employing a multi-step conceptual framework, summarized in Figure 1, which integrated data collected during childhood and/or adolescence on diet, metabolomics, and conventional cardiometabolic measures [fasting glucose and insulin, insulin resistance (assessed using the homeostatic model of assessment), HDL cholesterol, fasting triglycerides, and systolic blood pressure].

Figure 1. Conceptual diagram of the “meet in the middle” approach used to identify metabolites that mark the relationship between sugar sweetened beverage (SSB) intake and cardiometabolic risk.

(a) In step 1, we tested prospective associations of SSB intake in childhood with cardiometabolic risk
factors across childhood and adolescence. (b) In step 2, we identified plasma metabolites in childhood associated with SSB intake in childhood. (c) In step 3, we tested whether SSB-associated metabolites (from step 2) were also prospectively associated with SSB-associated CM risk factors across childhood and adolescence (from step 1). Abbreviations: FFQ, food frequency questionnaire; SSB, sugar-sweetened beverage.

2. Results
2.1. Characteristics

Background characteristics of the sample by quartile of energy-adjusted SSB intake in childhood (visit one) are shown in Table 1. The mean age of participants at the childhood visit increased across SSB quartiles (mean age ± SD for highest vs. lowest SSB quartile: 10.7 ± 1.5 vs. 10.2 ± 1.5, respectively; p = 0.023). There were also differences in the racial/ethnic distribution across SSB quartiles (p < 0.001), whereby the highest quartile versus the lowest quartile had a higher percentage of Hispanic participants (52 vs. 29%, respectively), but fewer non-Hispanic white participants (33 vs. 60%, respectively).

Table 1. Descriptive statistics of 597 EPOCH participants during childhood according to sugar sweetened beverage (SSB) intake.

| Variable                        | Quartile 1 (0 to 0.25 Servings/d) | Quartile 2 (0.26 to 0.54 Servings/d) | Quartile 3 (0.55 to 1.00 Servings/d) | Quartile 4 (1.01 to 5.12 Servings/d) | p-Value 2 |
|---------------------------------|-----------------------------------|---------------------------------------|--------------------------------------|------------------------------------|------------|
| N                               | Mean (SD) or Count (%)            | Mean (SD) or Count (%)                | Mean (SD) or Count (%)               | Mean (SD) or Count (%)             |            |
| Age (years), mean (SD)          | 148 (1.5)                         | 149 (1.4)                             | 10.5 (1.4)                           | 10.7 (1.5)                         | 0.023      |
| Male Sex, n (%)                 | 63 (43%)                          | 72 (48%)                              | 75 (50%)                             | 87 (58%)                           | 0.064      |
| Race/ethnicity, n (%):          |                                   |                                       |                                       |                                    | <0.001     |
| Hispanic                        | 43 (29%)                          | 52 (35%)                              | 57 (38%)                             | 78 (52%)                           |            |
| NH White                        | 89 (60%)                          | 77 (52%)                              | 71 (47%)                             | 49 (33%)                           |            |
| NH Black                        | 10 (7%)                           | 8 (5%)                                | 13 (9%)                              | 17 (11%)                           |            |
| NH Other                        | 6 (4%)                            | 12 (8%)                               | 9 (6%)                               | 6 (4%)                             |            |
| BMI z-score, mean (SD)          | 0.28 (1.30)                       | 0.19 (1.22)                           | 0.22 (1.21)                          | 0.37 (1.21)                        | 0.611      |
| Energy intake (kcal/d), mean (SD)| 1720 (501)                        | 1808 (503)                            | 1834 (527)                           | 1810 (649)                         | 0.292      |
| Pubertal stage, n (%):          |                                   |                                       |                                       |                                    | 0.793      |
| Pre-pubertal (Tanner = 1)       | 69 (49%)                          | 68 (48%)                              | 67 (47%)                             | 69 (49%)                           |            |
| Pubertal (Tanner = 2 or 3)      | 71 (51%)                          | 74 (52%)                              | 75 (53%)                             | 72 (51%)                           |            |
| Late/post-pubertal (Tanner = 4) | 0 (0%)                            | 0 (0%)                                | 0 (0%)                               | 0 (0%)                             |            |
| In utero GDM Exposure, n (%)    | 29 (20%)                          | 22 (15%)                              | 23 (15%)                             | 23 (16%)                           | 0.683      |
| SSB intake, serving/d, mean (SD)| 0.11 (0.09)                       | 0.39 (0.08)                           | 0.77 (0.13)                          | 1.86 (0.91)                        |            |

1 SSB intake quartiles were determined based on energy-adjusted SSB intake using the residual method.
2 Differences in each child’s characteristics by SSB intake quartile were assessed using analysis of variance (ANOVA) for continuous characteristics and Chi-squared tests for categorical characteristics. SSB intake was energy-adjusted using the residual method. Abbreviations: SSB, sugar sweetened beverages; BMI, body mass index; GDM, gestational diabetes mellitus.

2.2. Associations of SSB Intake in Childhood with Cardiometabolic Measures

The means and standard deviations for each cardiometabolic measure of interest at study visits in childhood and adolescence are shown in Table S1; generally, mean values for each cardiometabolic measure increased from childhood to adolescence, except for HDL cholesterol, which decreased. In linear mixed models adjusted for age, sex, and race/ethnicity, SSB intake in childhood was associated with higher fasting triglycerides across childhood/adolescence (β (95% CI) for highest versus lowest SSB intake quartile: 8.1 (−0.9, 17.0) mg/dL; p-trend = 0.057; Table 2). There were no notable associations between SSB intake in childhood and the other cardiometabolic risk factors (fasting glucose, fasting insulin, HOMA-IR, HDL cholesterol, or systolic blood pressure; Table 2). Thus, downstream analyses focused on triglycerides as the primary SSB-associated cardiometabolic outcome of interest.
Table 2. Prospective associations between sugar sweetened beverage (SSB) intake in childhood and cardiometabolic risk factors across childhood and adolescence.

SSB Intake in Childhood 1:

| Outcome                  | Quartile 2 vs. 1 | Quartile 3 vs. 1 | Quartile 4 vs. 1 | Linear Trend | p-Value 2,3 |
|--------------------------|-----------------|-----------------|-----------------|--------------|------------|
| Glucose (mg/dL)          | −0.7 (−4.1, 2.7)| −0.7 (−4.2, 2.7)| −1.4 (−4.9, 2.2)| 0.488        |
| Insulin (µIU/mL)         | −1.7 (−3.5, 0.1)| −1.1 (−2.9, 0.7)| −1.3 (−3.1, 0.6)| 0.426        |
| HOMA-IR                  | −0.7 (−1.3, −0.1)| −0.4 (−1.0, 0.2)| −0.5 (−1.1, 0.1)| 0.330        |
| HDL Cholesterol (mg/dL)  | −0.6 (−2.7, 1.6)| −0.8 (−3.0, 1.4)| −0.1 (−2.4, 2.1)| 0.973        |
| Triglycerides (mg/dL)    | 1.6 (−7.0, 10.3)| 4.9 (−3.8, 13.6)| 8.1 (−0.9, 17.0)| 0.057        |
| Systolic blood pressure (mm Hg) | −1.8 (−3.7, 0.2) | −1.0 (−3.0, 1.0) | −0.9 (−2.9, 1.1) | 0.770        |

1 SSB intake quartiles were determined based on energy-adjusted SSB intake using the residual method. 2 Estimates based on mixed-effects models adjusted for participant age across visits, sex, and race/ethnicity (Hispanic, non-Hispanic white, non-Hispanic black, or non-Hispanic other). All models included a participant-specific random intercept. 3 Linear trends across quartiles were assessed using the median value for each quartile. Abbreviations: HOMA-IR, homeostatic model of assessment for insulin resistance; HDL, high-density lipoprotein.

2.3. Associations of SSB Intake in Childhood with Plasma Metabolites

A total of 180 metabolites (out of 767 metabolites measured by the untargeted metabolomics assay) were selected in LASSO regression with log-transformed SSB intake as the dependent variable, whereby selection was defined as having a non-zero coefficient in ≥40% of the bootstrap samples, which was a data-driven threshold described in more detail in the Methods section under “Statistical Analyses”. Among these selected metabolites, 136 (76%) had confirmed identities. The metabolites selected in LASSO regression with SSB intake are summarized in Table 3, which also reports the number of times that the metabolite was selected across bootstrap samples (whereby, “selection” was defined as having a non-zero regression coefficient) and its average β-coefficient across bootstrap samples. The selected metabolites were primarily lipids (45 metabolites, 25%), amino acid-related (44 metabolites, 24%), or xenobiotics (21 metabolites, 12%).

Table 3. Metabolite features in childhood associated with sugar sweetened beverage intake in childhood, based on least absolute shrinkage and selection operator (LASSO) regression.
| Metabolite Name                     | Pathway                     | Sub-Pathway                  | Average β  | Count |
|------------------------------------|-----------------------------|------------------------------|------------|-------|
| N,N,N-trimethyl-5-aminovalerate    | Amino Acid                  | Lysine Metabolism            | 0.157      | 55    |
| Nε-acetyllysine                    | Amino Acid                  | Lysine Metabolism            | –0.165     | 41    |
| Cysteine s-sulfate                 | Amino acid                  | Methionine/cysteine/SAM metabolism | 0.124   | 68    |
| Methionine sulfone                 | Amino acid                  | Methionine/cysteine/SAM metabolism | 0.071   | 42    |
| Taurine                            | Amino acid                  | Methionine/cysteine/SAM metabolism | 0.165   | 57    |
| (N(1) + N(8))-acetylspermidine     | Amino Acid                  | Polyamine Metabolism         | 0.122      | 44    |
| 4-acetamidobutanoate              | Amino Acid                  | Polyamine metabolism         | –0.173     | 48    |
| Indoleacetate                     | Amino acid                  | Tryptophan metabolism        | 0.066      | 53    |
| Indolepropionate                  | Amino acid                  | Tryptophan metabolism        | –0.057     | 52    |
| Tryptophan betaine                | Amino acid                  | Tryptophan metabolism        | –0.045     | 62    |
| 3-methoxytyrosine                 | Amino acid                  | Tyrosine metabolism          | 0.268      | 71    |
| N-acetyltirosine                  | Amino Acid                  | Tyrosine Metabolism          | –0.116     | 53    |
| P-cresol glucuronide              | Amino Acid                  | Tyrosine Metabolism          | 0.030      | 42    |
| Phenol sulfate                     | Amino acid                  | Tyrosine metabolism          | –0.003     | 40    |
| Thryoxine                          | Amino acid                  | Tyrosine metabolism          | 0.090      | 42    |
| Tyramine O-sulfate                | Amino Acid                  | Tyrosine Metabolism          | 0.210      | 100   |
| Argininate                         | Amino acid                  | Urea cycle; arginine/proline metabolism | –0.094 | 57    |
| N-acetylarginine                   | Amino Acid                  | Urea cycle; arginine/proline metabolism | –0.121 | 43    |
| N-methylproline                    | Amino Acid                  | Urea cycle; arginine/proline metabolism | –0.029 | 40    |
| N-acetylglucosamine/galactosamine | Carbohydrate                | Amino sugar Metabolism        | –0.136     | 42    |
| Mannitol/sorbitol                  | Carbohydrate                | Hexose metabolism            | –0.045     | 49    |
| Arabitol/xylitol                   | Carbohydrate                | Pentose metabolism           | –0.230     | 62    |
| Arabanolate/xyleneilate           | Carbohydrate                | Pentose metabolism           | –0.096     | 40    |
| Ribonate                           | Carbohydrate                | Pentose metabolism           | –0.094     | 41    |
| Ribulonate/xylulonate              | Carbohydrate                | Pentose metabolism           | 0.121      | 54    |
| Galonate                           | Carbohydrate                | Ascorbate/aldarate metabolism | 0.144      | 55    |
| Threonate                          | Carbohydrate                | Ascorbate/aldarate metabolism | 0.047     | 45    |
| 1-methylnicotinamide              | Carbohydrate                | Nicotinate/nicotinamide metabolism | 0.352   | 92    |
| Quinolinolate                      | Carbohydrate                | Nicotinate/arginine/proline metabolism | –0.058 | 58    |
| Trigonelline (N'-methylnicotinate) | Carbohydrate                | Nicotinate/arginine/proline metabolism | –0.115 | 40    |
| Panthenol                          | Carbohydrate                | Vitamin A metabolism         | –0.047     | 50    |
| Beta-cryptoxanthin                 | Carbohydrate                | Vitamin A Metabolism          | 0.110      | 41    |
| Retinol (Vitamin A)                | Carbohydrate                | Vitamin A Metabolism          | –0.239     | 61    |
| Pyridoxate                         | Carbohydrate                | Vitamin B6 metabolism        | –0.084     | 47    |
| Deoxyxycarnitine                   | Carbohydrate                | Carnitine metabolism         | –0.129     | 46    |
| Ceramide (d18:1/14:0, d16:1/16:0) * | Lipid                       | Ceramides                    | 0.115      | 50    |
| N-stearoyl-sphingadienine (d18:2/18:0) * | Lipid                | Ceramides                    | –0.289     | 86    |
| Palmitoyl-arachidonoyl-glycerol (36:4) * | Lipid                | Dicylglycerol                | –0.067     | 45    |
| Palmitoyl-linoeoyl-glycerol (16:0/18:2) * | Lipid                | Dicylglycerol                | 0.096      | 44    |
| Stearoyl-arachidonoyl-glycerol (18:0/20:4) * | Lipid                | Dicylglycerol                | –0.079     | 41    |
| N-deoxyserine                      | Lipid                       | Endocannabinoid              | 0.227      | 61    |
| Adipoylcarnitine (C6-DC)           | Lipid                       | Fatty Acid Metabolism (Acyl Carnitine) | 0.085   | 55    |
| Laurylcarnitine (C12)              | Lipid                       | Fatty Acid Metabolism (Acyl Carnitine) | 0.124     | 44    |
| Linolenoylcarnitine (C18:3) *      | Lipid                       | Fatty Acid Metabolism (Acyl Carnitine) | 0.083     | 42    |
| 3-hydroxybutyroylglycine *         | Lipid                       | Fatty acid metabolism (Acyl Glycine) | –0.066     | 50    |
| N-palmitoylglycine                 | Lipid                       | Fatty Acid Metabolism (Acyl Glycine) | –0.187     | 52    |
| Hexadecenodecadienole (C16:1-DC) * | Lipid                       | Fatty Acid/Dicarboxylate     | –0.252     | 65    |
| Octadecadienoleoic (C18:2-DC) *    | Lipid                       | Fatty Acid/Dicarboxylate     | 0.107      | 67    |
| Sebacate (C10-DC)                  | Lipid                       | Fatty Acid/Dicarboxylate     | –0.063     | 41    |
| Tetradecanoic (C14-DC)             | Lipid                       | Fatty Acid/Dicarboxylate     | –0.317     | 77    |
| 12,13-dihomo                       | Lipid                       | Fatty Acid/Dihydroxy         | 0.063      | 41    |
| 2-hydroxylaurate                   | Lipid                       | Fatty acid/monoxydroxy       | 0.303      | 78    |
| 2-hydroxyoxeronate                 | Lipid                       | Fatty acid/monoxydroxy       | 0.174      | 56    |
| Glycosyl ceramide (d38:1) *        | Lipid                       | Hexosylceramides (HCER)      | 0.339      | 79    |
| Glycosyl-N-stearoyl-sphingosine (d36:1) * | Lipid                | Hexosylceramides (HCER)      | 0.160      | 43    |
| Lactosyl-N-benhenooyl-sphingosine (d40:1) * | Lipid                | Lactosylceramides (LCER)     | –0.230     | 84    |
| Arachidate (20:0)                  | Lipid                       | Long chain fatty acid        | 0.127      | 48    |
| Margarate (17:0)                   | Lipid                       | Long chain fatty acid        | 0.217      | 44    |
| 1-linolenoyl-GPC (18:2) *          | Lipid                       | Lyso phospholipid            | 0.091      | 41    |
| 1-arachidonoyl-glycerol (20:4)     | Lipid                       | Monacylglycerol              | 0.108      | 58    |
| 1-linolenoyl-glycerol (18:3)       | Lipid                       | Monacylglycerol              | 0.182      | 84    |
| 1-oleoyl-glycerol (18:1)           | Lipid                       | Monacylglycerol              | 0.105      | 47    |
| 2-arachidonoylglycerol (20:4)      | Lipid                       | Monacylglycerol              | 0.083      | 56    |
| 1-myristoyl-2-arachidinoyl-GPC (34:4) * | Lipid                | Phosphatidylcholine (PC)     | –0.122     | 42    |
Table 3. Cont.

| Metabolite Name 1 | Pathway | Sub-Pathway | Average β 2 | Count 3 |
|------------------|---------|-------------|-------------|---------|
| 1-stearoyl-2-oleoyl-GPC (18:0/18:1) | Lipid | Phosphatidylcholine (PC) | 0.440 | 64 |
| 1,2-dipalmitoyl-GPC (16:0/16:0) | Lipid | Phosphatidylcholine (PC) | 0.466 | 57 |
| 1-palmitoyl-2-arachidonoyl-GPI (36:4) 4 | Lipid | Phosphatidylinositol (PI) | 0.199 | 66 |
| 1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-36:4) 4 | Lipid | Plasmalogen | 0.166 | 44 |
| 1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-32:1) 4 | Lipid | Plasmalogen | −0.173 | 64 |
| Adrenate (22:4n6) | Lipid | Polysaturated fatty acid (n3/n6) | 0.117 | 52 |
| Glycocenodeoxycholate | Lipid | Primary bile acid metabolism | −0.035 | 41 |
| Taurocholate | Lipid | Primary bile acid metabolism | 0.057 | 54 |
| Glycolithocholate sulfate 4 | Lipid | Secondary bile acid metabolism | −0.044 | 45 |
| Lithocholate sulfate (1) | Lipid | Secondary bile acid metabolism | −0.037 | 42 |
| Sphinganine-1-phosphate | Lipid | Sphingolipid synthesis | −0.147 | 63 |
| Sphingomyelin (d43:1) 4 | Lipid | Sphingomyelins | −0.280 | 74 |
| Sphingomyelin (d42:4) 4 | Lipid | Sphingomyelins | 0.201 | 45 |
| 7-alpha-hydroxy-3-oxo-4-cholestenoate | Lipid | Sterol | −0.082 | 42 |
| Allantoin | Nucleotide | Purine metabolism: xanthine/inosine | −0.376 | 80 |
| Adenine | Nucleotide | Purine metabolism: adenine | −0.147 | 42 |
| Guanosine | Nucleotide | Purine metabolism: guanine | −0.145 | 97 |
| N2,N2-dimethylguanosine | Nucleotide | Purine Metabolism: guanine | 0.279 | 46 |
| Orotic acid | Nucleotide | Pyrimidine metabolism: orotate | −0.238 | 73 |
| Orotidine | Nucleotide | Pyrimidine metabolism: orotate | 0.073 | 41 |
| 3-aminoisobutyrate | Nucleotide | Pyrimidine metabolism: thymine | 0.059 | 46 |
| 5,6-dihydrothymine | Nucleotide | Pyrimidine metabolism: thymine | 0.181 | 65 |
| Leucylalanine | Peptide | Dipeptide | 0.044 | 47 |
| Gamma-glutamylcitrulline 4 | Peptide | Gamma-glutamyl amino acid | −0.056 | 42 |
| 3-methoxycatechol sulfate (1) | Xenobiotics | Benzoate metabolism | 0.082 | 81 |
| 3-phenylpropionate (hydrocinnamate) | Xenobiots | Benzene metabolism | −0.057 | 61 |
| 4-ethylhexyl sulfate | Xenobiots | Benzene metabolism | 0.027 | 48 |
| 4-hydroxyhippurate | Xenobiots | Benzene metabolism | 0.087 | 52 |
| 4-methylguaiacol sulfate | Xenobiots | Benzene metabolism | 0.041 | 40 |
| Methyl-4-hydroxybenzoate sulfate | Xenobiots | Benzene metabolism | 0.046 | 75 |
| 2-naphthol sulfate | Xenobiots | Chemical | 0.029 | 45 |
| 3-hydroxypropridyl sulfate | Xenobiots | Chemical | −0.042 | 45 |
| Perfluoroctanoate (PFOA) 4 | Xenobiots | Chemical | −0.141 | 62 |
| Sulfate 4 | Xenobiots | Chemical | 0.336 | 56 |
| Hydroquinone sulfate | Xenobiots | Drug–topical agents | −0.185 | 92 |
| 2-isopropylmalate | Xenobiots | Food component/plant | −0.064 | 47 |
| 2-piperidinone | Xenobiots | Food component/plant | −0.040 | 52 |
| 2,3-dihydroxyisovalerate | Xenobiots | Food component/plant | −0.050 | 52 |
| 3,4-methyleneheptanoate | Xenobiots | Food component/plant | 0.059 | 50 |
| Ergothioneine | Xenobiots | Food component/plant | −0.400 | 98 |
| Erythritol | Xenobiots | Food component/plant | 0.110 | 51 |
| Glucuronide of piperine metabolite 4 | Xenobiots | Food Component/Plant | −0.039 | 45 |
| Pyrulline | Xenobiots | Food component/plant | −0.088 | 64 |
| Thymol sulfate | Xenobiots | Food component/plant | −0.030 | 59 |
| 5-acetylamo-6-amino-3-methyluracil | Xenobiots | Xanthine metabolism | 0.097 | 90 |

1 This table only shows the metabolites that were identified. A total of 44 unknown metabolites are not shown.
2 Average β-coefficients were calculated as the average of all regression coefficients for each metabolite across 100 bootstrap samples.
3 Indicates the number of times the metabolite was selected (based on having a non-zero coefficient) across 100 bootstrap samples. Metabolites shown here were selected in ≥40% of bootstrap samples.
4 Indicates tier 2 identification in which no commercially available authentic standard can be found; however, it was annotated based on accurate mass, spectral, and chromatographic similarity to tier 1-identified compounds.

2.4. Associations of SSB-Related Metabolites in Childhood with Triglycerides

In Table 4, we show the subset of SSB-associated metabolites (from step two, reported in Table 3) that were also associated with fasting triglycerides (the primary cardiometabolic outcome of interest from step one/Table 2) across childhood and adolescence in linear mixed models adjusted for age, sex, and race/ethnicity. Of the 180 metabolites associated with SSB intake in childhood, 13 metabolites were also associated with triglycerides across childhood and adolescence in the same direction as their association with SSB intake in childhood, based on a Bonferroni-adjusted p < 0.00028 (α = 0.05/180 metabolites; Table 4). Among these 13 metabolites, 11 metabolites were lipid metabolites, while the remaining 2 were unknown metabolites (Table 4). The identified metabolites included four dicarboxy-
lated fatty acids (chain lengths ranging 10 to 16), a lactosylceramide, and a plasmalogen, which were inversely associated with triglycerides (Table 4). There were also several mono-and diacylglycerols and phospholipids, which were positively associated with triglycerides (Table 4). Scatter plots visualizing the relationship between these lipid metabolites in childhood and triglycerides across childhood and adolescence are shown in Figure S1. Table S2 summarizes the full results from this step, i.e., associations between all 180 SSB-associated metabolites in childhood and triglycerides across childhood and adolescence, based on linear mixed models.

Table 4. Prospective associations between the selected metabolites associated with sugar-sweetened beverage intake in childhood and fasting triglycerides across childhood and adolescence.

| Metabolite Name                                      | Pathway   | Sub-Pathway   | $\beta$ (95% CI) | p-Value  |
|-----------------------------------------------------|-----------|---------------|------------------|----------|
| Palmitoyl-linoleoyl-glycerol (16:0/18:2) *           | Lipid     | Dicacylglycerol| 78.3 (66.3, 90.2) | $<1.00 \times 10^{-7}$ |
| Tetradecenedioate (C14-DC)                          | Lipid     | Fatty Acid/Dicarboxylate | $-35.9 (-51.2, -20.5)$ | $3.79 \times 10^{-6}$ |
| Hexadecenedioate (C16:1-DC) *                       | Lipid     | Fatty Acid/Dicarboxylate | $-30.9 (-46.3, -15.6)$ | $8.35 \times 10^{-5}$ |
| Hexadecanedioate (C16-DC)                           | Lipid     | Fatty Acid/Dicarboxylate | $-40.0 (-56.7, -23.2)$ | $8.47 \times 10^{-6}$ |
| Sebacate (C10-DC)                                   | Lipid     | Fatty Acid/Dicarboxylate | $-31.6 (-45.4, -17.8)$ | $6.15 \times 10^{-6}$ |
| Lactosyl-N-behenoyl-sphingosine (d40:1) *           | Lipid     | Lactosylceramides (LCER) | $-39.6 (-55.4, -23.8)$ | $1.23 \times 10^{-6}$ |
| 1-linolenoylglycerol (18:3)                         | Lipid     | Monoacylglycerol  | 46.6 (35.7, 56.6) | $<1.00 \times 10^{-7}$ |
| 1-oleoylglycerol (18:1)                             | Lipid     | Monoacylglycerol  | 88.3 (73.9, 102.7) | $<1.00 \times 10^{-7}$ |
| 1-stearoyl-2-oleoyl-GPC (18:0/18:1)                 | Lipid     | Phosphatidylcholine (PC) | 76.1 (47.7, 104.5) | $2.26 \times 10^{-7}$ |
| 1-palmitoyl-2-arachidonoyl-GPI (36:4) *             | Lipid     | Phosphatidylinositol (PI) | 71.6 (56.6, 86.6) | $<1.00 \times 10^{-7}$ |
| 1-[(1-enyl-palmitoyl)-2-palmitoleoyl-GPC           | Lipid     | Plasmalogen     | $-69.3 (-92.8, -45.7)$ | $<1.00 \times 10^{-7}$ |

1 This table only shows the 11 metabolites that were identified. A total of 2 unknown metabolites are not shown.

2 Estimates based on linear mixed-effects models adjusted for participant age across visits, sex, and race/ethnicity (Hispanic, non-Hispanic white, non-Hispanic black, or non-Hispanic other). All models included a participant-specific random intercept. 3 Displaying raw $p$-values from linear mixed effects models. Only metabolites with a $p$-value less than the Bonferroni-corrected $p < 0.000278$ (0.05/180 metabolite tests or $2.78 \times 10^{-5}$) and with an estimate in the same direction as with SSB intake in childhood are shown. * Indicates tier 2 identification in which no commercially available authentic standard can be found; however, it was annotated based on accurate mass, spectral, and chromatographic similarity to tier 1 identified compounds.

2.5. Sensitivity Analyses

In sensitivity analyses, we observed similar findings when we additionally adjusted each step for pubertal stage, which may be a mediator of the relationship between SSB intake and the cardiometabolic outcomes. Specifically, in step one, the association between SSB intake in childhood and triglycerides across childhood and adolescence was similar in magnitude and direction ($\beta$ (95% CI): 7.4 (−1.5, 16.4) mg/dL for the highest versus lowest quartile of SSB intake; p-trend = 0.075). In step two, the LASSO regression selected a similar set of metabolites that were associated with SSB intake in childhood (170 metabolites were selected in >40% bootstrap samples, among which 153 (90%) were also selected in LASSO regression before adjusting for pubertal stage). In step three, the subset of SSB-associated metabolites from step two that were also associated with triglycerides across childhood and adolescence consisted of 11 of the 13 metabolites selected in the primary analysis above without adjusting for pubertal stage (two of the dicarboxylated fatty acids were not selected), which are summarized in Table S3.

3. Discussion

In this longitudinal cohort of diverse youth, we integrated data on diet, untargeted metabolomics, and conventional cardiometabolic risk factors using a “meet in the middle” approach to identify plasma metabolite alterations that link SSB intake in childhood with cardiometabolic risk across childhood adolescence. First, we found that energy-adjusted SSB intake was associated with higher fasting triglycerides across childhood and adolescence in this sample, but no other cardiometabolic risk factors (glucose, insulin, HOMA-IR, HDL cholesterol, or systolic blood pressure). Subsequently, we used robust selection criteria to identify 13 plasma metabolites that were associated both with SSB intake in childhood and with triglycerides across childhood and adolescence with the same directionality. All
the metabolites that could be identified (11 of 13) were lipid-related metabolites, particularly dicarboxylated fatty acids, mono- and diacylglycerols, and phospholipids. This pattern of metabolite alterations may, therefore, reflect disruptions in lipid metabolism that causally link higher SSB intake in childhood with dyslipidemia risk, which will need to be investigated in future studies.

In the first step of the analysis, we found that childhood SSB intake was associated with higher triglycerides across childhood and adolescence, consistent with the literature [21]. This effect may be due to unregulated hepatic fructose metabolism [22], which can lead to hepatic substrate overload and increased hepatic de novo lipogenesis [23,24]. Fructose intake may also alter hepatic lipid metabolism by stimulating lipogenic gene expression via the activation of several transcriptional activator families, including carbohydrate-responsive element-binding protein (ChREBP), sterol regulatory element-binding protein (SREBP), and peroxisome proliferator-activated receptor (PPAR) [23,24], as well as indirectly by inhibiting fat oxidation [25]. Over time, these metabolic alterations contribute to intrahepatic lipid accumulation, which can promote a compensatory increase in the production and secretion of very-low-density lipoproteins (VLDLs), leading to higher plasma triglycerides, as we observed in this study. It was unexpected that we did not find significant associations of SSB intake in childhood with any of the other cardiometabolic risk factors. However, this aligns with the findings from a few other studies of relatively healthy populations, which also found a preferential association of SSB intake with lipids, but not with other markers of glucose-insulin homeostasis [26]. It is possible that disruptions in fasting triglycerides are a ‘first step’ in the metabolic milieu associated with SSB intake and that more prolonged exposure is needed to observe other associations, particularly among otherwise healthy youth.

After evaluating prospective associations between SSB intake and cardiometabolic outcomes, we identified the 180 plasma metabolites that were most strongly associated with SSB intake at the childhood visit using LASSO regression. LASSO is a data-driven, multivariate analytical technique that is ideally suited for dimension reduction and feature selection. These 180 metabolites were primarily related to lipid, amino acid, and xenobiotic metabolism pathways. In comparing the findings of the present study with published literature, we noted that one metabolite selected by LASSO, taurine, was one of the four urinary metabolites identified as a biomarker of SSB intake in a study of adults in Ireland by Gibbons et al. [18]. This consistent association may be because taurine is often an added ingredient (along with caffeine) in sugar-sweetened energy drinks, although, it is worth noting that circulating taurine may also be influenced by other food sources, such as meat and seafood, as well as endogenous taurine biosynthesis via methionine and cysteine metabolism [27]. The other three metabolites on the panel selected by Gibbons et al. (formate, isocitrate, and citrulline) were not selected by LASSO regression in this study, which may be due to differences in the biospecimen analyzed (i.e., urine versus blood) or the age range of the participants (i.e., adults versus children). We also note that none of the metabolites associated with SSB intake in this study overlapped with the metabolites associated with SSB intake in a similar analysis by Perng et al. based on the ELEMENT Project in Mexico City [20]. This may be due to differences in the geography of each cohort (including the composition and overall intake patterns of SSBs in the U.S. versus Mexico), as well as the untargeted metabolomics platforms employed (Metabolon in EPOCH vs. University of Michigan’s Metabolomics Research Core in ELEMENT) and the nuances of the analytical strategies used in each study. Collectively, this highlights the challenges in identifying dietary biomarkers that are consistent across different populations.

In the final step of our analysis, we filtered the 180 metabolites associated with SSB intake in childhood to 13 metabolites that were also associated with triglycerides across childhood and adolescence, which was the primary cardiometabolic outcome of interest. Except for two unknowns, all of these metabolites were identified as lipids. Specifically, four metabolites were dicarboxylated fatty acids, which are fatty acids with two carboxyl groups that can be generated from ω-oxidation or plant/vegetable intake [28] and have
been shown to be markedly lower in children with obesity versus controls [29]. In this study, we also found inverse associations of dicarboxylated fatty acids with SSB intake and triglycerides, potentially reflecting disruptions in fatty acid catabolism/oxidation—a plausible metabolic disturbance that could be mediated by fructose-induced alterations in PPAR-alpha activity [30] and, in turn, contribute to elevated triglycerides. Other identified metabolites were two monoacylglycerols and one diacylglycerol, which were positively associated with SSB intake and triglycerides. This finding corroborates other studies showing that the accumulation of these lipid intermediates is associated with poorer cardiometabolic health [31,32], possibly via disruptions in insulin signaling and mitochondrial dysfunction [33,34], and, further, that their plasma levels were responsive to a healthy dietary pattern (Mediterranean diet) intervention [31].

Other lipid metabolites identified in this final step of our analysis included three glycerophospholipids and one lactosylceramide, a type of sphingolipid. Phospholipid alterations assessed by metabolomics or lipidomics have been consistently associated with cardiometabolic diseases, including diabetes/prediabetes and cardiovascular disease [35,36]. One of the phospholipids identified was 1-stearoyl-2-oleoyl-GPC (18:0/18:1), a common phosphatidylcholine (PC) found in animal membranes that was positively associated with SSBS and triglycerides in this study. This aligns with findings from a dietary intervention in adults showing that the same PC was directly associated with changes in triglycerides following an 8-week low-calorie diet [37]. The potential mechanisms underlying these associations warrant further investigation but may reflect the close link between hepatic phospholipid metabolism and triglyceride packaging and secretion from the liver [38].

A limitation was our reliance on a self-reported dietary assessment to quantify SSB intake, which can be prone to several biases (recall bias, social desirability bias, etc.), especially in children/adolescents with obesity [39]. However, because we assessed the relationship between dietary intake and the cardiometabolic outcomes prospectively, it is less likely that any reporting bias was differential with respect to the outcome. Moreover, we adjusted SSB intake for total energy intake for analyses, which may mitigate measurement error and improve the precision of estimates [40]. The metabolomics assay used was semi-quantitative in nature; thus, additional, targeted assays would be needed to assess absolute concentrations for metabolites. In addition, the sample was from one geographic region (Colorado, USA), which may limit the generalizability of our findings. Strengths of this study include the longitudinal study design, which allowed us to assess prospective associations between SSB intake and metabolome alterations in childhood with repeated measures of cardiometabolic risk, and the use of a comprehensive untargeted metabolomics profiling technique combined with a multivariate method (LASSO regression) with proven utility to protect against false positive findings for variable selection/dimension reduction. Additionally, the extensive laboratory, metabolic, anthropometric, and behavioral assessments performed on the EPOCH cohort allowed us to adjust for various potential confounding factors, and the relatively large sample size (~600 participants), especially compared to other metabolomics datasets in youth cohorts, provided statistical power to assess potential effect modification by sex.

Conclusions

In a longitudinal, multiethnic cohort of children based in Colorado, we identified 13 metabolites, 11 of which were involved in lipid metabolic pathways, that link the prospective relationship between SSB intake in childhood with fasting triglyceride levels across childhood and adolescence. These intermediary lipid metabolites may not only represent potential biomarkers of higher SSB intake in youth but also may reflect underlying metabolic disruptions that are causally involved in the adverse effects of SSB intake on plasma triglycerides, supporting their prioritization in future investigations. Specifically, in addition to other prospective studies validating the utility of these metabolites as SSB biomarkers, experimental studies are needed to further understand the potential mech-
anisms underlying this interplay between SSB intake, lipid metabolite disruptions, and dyslipidemia in youth. This study also adds to the growing body of literature supporting a link between SSB intake and cardiometabolic abnormalities in youth, which supports the importance of more research aiming to identify and target factors that may influence childhood SSB intake, such as parental/family-, school/community-, or policy-related factors [41–43].

4. Materials and Methods

4.1. Study Population

This study included participants from the EPOCH study, a longitudinal, multiethnic cohort of youth in Colorado. The original aim was to examine the health effects on offspring of in utero exposure to maternal gestational diabetes mellitus (GDM) [44]. Participants were the offspring of mothers who were members of the Kaiser Permanente of Colorado (KP CO) health plan. We enrolled children who were exposed to maternal diabetes in utero (n = 99) and a random sample of children who were not exposed to maternal diabetes (n = 505). The first research visit occurred from 2006 to 2009, when offspring were 6–14 years old (median 10.6 years; “visit 1”). Among these participants, 413 returned for a second visit from 2012 to 2015 when offspring were 12–19 years old (median 16.8 years; “visit 2”). Mothers provided written informed consent and children participants provided written assent. This study was approved by the Colorado Multiple Institutional Review Board (Protocol no. 05-0623).

For this analysis, we excluded two participants who were missing dietary data at visit 1 and five participants with insufficient blood volume for metabolomics analysis at visit 1, resulting in an analytical sample of 597 participants. In analyses examining the prospective associations with cardiometabolic risk factors across childhood and adolescence, we also excluded the following participants who were missing data both at visit 1 and visit 2 for the following measures (i.e., no data at either visit for the outcome of interest): n = 1 missing glucose at both visits; n = 3 missing insulin and HOMA-IR at both visits; n = 5 missing HDL cholesterol at both visits; n = 1 missing triglycerides at both visits. Participant selection is summarized in Figure 2.

Figure 2. Selection of study participants from the Exploring Perinatal Outcomes among Children (EPOCH) Study. Abbreviations: CM, cardiometabolic; HOMA-IR, homeostatic model of assessment-insulin resistance; HDL, high-density lipoprotein.
4.2. Dietary Assessment

Dietary intake was assessed at both visits using a modified version of the Block Kids Food Frequency Questionnaire [45], a semi-quantitative food frequency questionnaire that has been validated in children as young as 8 years old [46,47]. The questionnaire queried whether the participant consumed each food/beverage item in the past week and, if so, how many days per week (ranging from ‘one day’ to ‘every day’) and the usual amount eaten per day. The full questionnaire may be available upon reasonable request. Completed questionnaires were then analyzed to estimate individual intakes of total energy, nutrients, and food groups per day. For each participant, SSB intake in childhood was assessed by summing the servings per day from the following: sodas, fruit drinks (i.e., Sunny Delight, Hawaiian Punch, etc.), sports drinks (i.e., Gatorade), and sweetened tea or coffee. We used the residual method to adjust SSB intake for total energy intake per day [48]. Participants were then grouped based on their quartile of energy-adjusted SSB intake for later analyses.

4.3. Untargeted Metabolomics Profiling of Plasma

Fasting blood samples were collected from all participants at both visits by trained phlebotomists. All samples were refrigerated immediately, processed within 24 h, and stored at −80 °C until the time of analysis. As previously described [49,50], untargeted metabolomics profiling was performed on stored fasting plasma samples by Metabolon using a multiplatform mass spectroscopy-based technique, which identified 1193 unique features at both time points. Prior to formal statistical analysis, we removed metabolites with ≥20% missing values per batch. The remaining missing values were imputed using the K-nearest neighbor algorithm (with K = 10) [51]. The samples were analyzed in two batches: the first batch of participants had 913 metabolites after removing those with high missingness, and the second batch had 898 metabolites. We then merged the two batches for subsequent data processing and retained 767 metabolites that were present in both batches. The retained metabolites then underwent log_{10}-transformation, followed by metabolite normalization and correction for batch effects (as well as other biological and technical variability) using the remove unwanted variation method (with K = 2 factors of unwanted variation estimated from the data) [52]. All the above preprocessing steps were performed using R Statistical Software (version 3.5.3) [53].

4.4. Cardiometabolic Risk Assessments

We used fasting blood samples from both visits to assess the following markers of cardiometabolic risk across childhood and adolescence. Fasting glucose was assessed enzymatically, and fasting insulin was assessed by using radioimmunoassay (Millipore, Darmstadt, Germany). Fasting glucose and insulin were then used to estimate insulin resistance using the homeostatic model of assessment (HOMA-IR) [54] Fasting blood lipids, including HDL cholesterol and triglycerides, were assayed on the Olympus AU400 advanced chemistry analyzer system. At both visits in childhood and adolescence, participants’ blood pressure was also measured twice in the sitting position using an oscillometric monitor (Dinamap ProCare V100). For this analysis, we used the average of the two values and focused on systolic blood pressure only.

4.5. Other Covariate Assessments

Exposure to maternal GDM during pregnancy was ascertained from the KPCO perinatal database and defined as a physician’s diagnosis of gestational diabetes based on routine screening at 24–28 weeks of gestation using the standard two-step protocol [55]. Child race/ethnicity was self-reported at visit 1 as being non-Hispanic white, non-Hispanic black, Hispanic, or non-Hispanic other. The child’s height (kg) and weight (cm) were assessed at both visits by trained research staff while wearing light clothing and without shoes. These measurements were used to calculate age- and sex-specific body mass index (BMI) z-scores using the WHO growth reference for children aged 5–19 years [56]. At both visits, participants reported their pubertal development based on pictorial diagrams of the
Tanner stages, which had been validated against physician-assessed Tanner staging and puberty-related hormones [57], and which bases pubertal stage on pubic hair development in boys and breast development in girls. Participants were then categorized as pre-pubertal (Tanner = 1), pubertal (Tanner = 2 or 3), and late/post-pubertal (Tanner = 4 or 5).

4.6. Statistical Analyses

We first examined bivariate associations between energy-adjusted SSB intake quartiles in childhood and the background characteristics of the sample in childhood. For categorical variables, we reported counts and frequencies for each sub-category according to SSB intake quartile and tested differences across quartiles using Chi-squared tests. For continuous variables, we reported means and standard deviations according to SSB quartile and tested for differences across SSB quartiles using a one-way analysis of variance (ANOVA).

Next, a “meet in the middle” approach was employed to identify the plasma metabolites that may mark the relationship between SSB intake and cardiometabolic risk. In the first step, we examined the associations of SSB quartiles in childhood (visit 1) with repeated measures of cardiometabolic risk (fasting glucose, fasting insulin, HOMA-IR, HDL cholesterol, fasting triglycerides, and systolic blood pressure) across childhood and adolescence (visit 1 and visit 2) using mixed-effects models adjusted for child age, sex, and race/ethnicity. Models included a random intercept for each participant ID to account for intra-individual correlations in cardiometabolic measures across visits and an unstructured covariance matrix. We assessed effect modification by sex using product interaction terms, but none reached significance (all \( p > 0.10 \)); therefore, all analyses were conducted on the entire sample. Results are reported as regression coefficients and 95% confidence intervals for the 2nd, 3rd, and 4th quartiles of SSB intake when compared to the 1st quartile (the reference). We also tested for a linear trend across quartiles using a continuous variable based on the median value for each SSB quartile. For this step, we considered cardiometabolic risk factors for further exploration in downstream analyses if \( p < 0.10 \) for a linear trend across SSB quartiles.

In the second step, we identified plasma metabolites that were cross-sectionally associated with SSB intake in childhood (visit 1) by employing LASSO regression [58], using the \texttt{glmnet} package in R [53]. Briefly, LASSO is a regularized regression technique designed to select the strongest variables associated with an outcome of interest from a high-dimensional and correlated set of predictors. This is done by imposing a tuning parameter on the model that shrinks the regression coefficients for weaker variables to zero during feature selection, thereby removing weak but statistically significant associations that may represent false positive findings. Ten-fold cross validation was used to determine the tuning parameter that achieved the minimum mean error. To perform more stabilizing of variable selection, instead of running once, LASSO regression was carried out with 100 bootstrap samples with log-transformed SSB intake in childhood as the dependent variable and with adjustments for child age, sex, and race/ethnicity, as unpenalized variables. Metabolites were considered for downstream analyses if they were selected by LASSO (i.e., non-zero coefficient) in \( \geq 40\% \) of bootstrap samples. This threshold was determined by firstly calculating the number of metabolites selected, on average, across the 100 bootstrap iterations (202 metabolites selected on average). We then calculated the number of metabolites selected per 5-unit threshold increment and chose a threshold that selected a number of metabolites closest to the average from bootstrapping (180 metabolites were selected with a threshold of \( \geq 40\% \)).

In the third step, we investigated whether SSB-associated metabolites in childhood (selected from step 2) were also associated with SSB-associated cardiometabolic risk factors across childhood and adolescence (selected from step 1) using a second set of linear mixed-effects models with each metabolite as the independent variable and the repeated measures of each cardiometabolic measure across childhood and adolescence used as the dependent variable. Models were again adjusted for age, sex, and race/ethnicity, and included a random intercept for each participant’s ID and an unstructured covariance matrix. Results
are reported as regression coefficients and 95% CIs for the effect of a 1 unit increase in each metabolite on cardiometabolic measures. Metabolites were selected as being intermediary biomarkers if the regression coefficient’s p-value was below a Bonferroni-adjusted threshold ($\alpha = 0.05/\text{number of metabolites tested}$) and if the direction of the association with the cardiometabolic measure was the same as with the SSB intake. We also performed a sensitivity analysis where we additionally adjusted each step of the analysis for pubertal stage (pre-pubertal, pubertal, or late-pubertal), which can also affect cardiometabolic status during childhood [59]. Unless otherwise stated, statistical analyses were performed using SAS Statistical Software (version 9.4; Cary, NC, USA).

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/metabo12060559/s1, Figure S1: Associations between plasma metabolites in childhood (selected from Table 4) with triglycerides across childhood and adolescence, Table S1: Means and standard deviations for the cardiometabolic measures of interest at each visit in childhood and adolescence, Table S2: Prospective associations between all 180 metabolites associated with sugar sweetened beverage intake in childhood (from step 2) and fasting triglycerides across childhood and adolescence, Table S3: Sensitivity Analysis—Prospective associations between select metabolites associated with sugar sweetened beverage intake in childhood and triglycerides across childhood and adolescence with additional adjustment for pubertal stage.

Author Contributions: Conceptualization and methodology, W.P. and C.C.C.; formal analysis, C.C.C. and L.T.; resources, G.M.; writing—original draft preparation, C.C.C. and W.P.; writing—review and editing, D.D., G.M., L.T., K.S., M.I.G., W.P.; supervision, W.P.; funding acquisition, D.D. All authors have read and agreed to the published version of the manuscript.

Funding: The Exploring Perinatal Outcomes among CHildren (EPOCH) cohort was funded by the National Institutes of Health (NIH) National Institute of Diabetes, Digestive and Kidney Disease (NIDDK) grant no. R01-DK068001 to Dr. Dabelea. Dr. Cohen was supported by NIDDK grant no. T32-DK007658. Dr. Perng was supported by NIH National Center for Advancing Translational Sciences (NCATS) Colorado CTSA grant no. KL2-TR002534.

Institutional Review Board Statement: The study was approved by Colorado Multiple Institutional Review Board (#09-0563). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed Consent Statement: Mothers provided written informed consent and children provided written assent.

Data Availability Statement: Data are available upon reasonable request.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Hu, F.B. Resolved: There is sufficient scientific evidence that decreasing sugar-sweetened beverage consumption will reduce the prevalence of obesity and obesity-related diseases. *Obes. Rev.* **2013**, *14*, 606–619. [CrossRef] [PubMed]
2. Te Morenga, L.; Mallard, S.; Mann, J. Dietary sugars and body weight: Systematic review and meta-analyses of randomised controlled trials and cohort studies. *BMJ* **2012**, *346*, e7492. [CrossRef] [PubMed]
3. Vartanian, L.R.; Schwartz, M.B.; Brownell, K.D. Effects of soft drink consumption on nutrition and health: A systematic review and meta-analysis. *Am. J. Public Health* **2007**, *97*, 667–675. [CrossRef] [PubMed]
4. Sigala, D.M.; Stanhope, K.L. An Exploration of the Role of Sugar-Sweetened Beverage in Promoting Obesity and Health Disparities. *Curr. Obes. Rep.* **2021**, *10*, 39–52. [CrossRef] [PubMed]
5. Eny, K.M.; Jeyakumar, N.; Dai, D.W.H.; Maguire, J.L.; Parkin, P.C.; Birken, C.S.; Collaboration, T.A.K. Sugar-containing beverage consumption and cardiometabolic risk in preschool children. *Prev. Med. Rep.* **2020**, *17*, 101054. [CrossRef] [PubMed]
6. Seferidi, P.; Millett, C.; Laverty, A.A. Sweetened beverage intake in association to energy and sugar consumption and cardiometabolic markers in children. *Pediatr. Obes.* **2018**, *13*, 195–203. [CrossRef]
7. Stanhope, K.L.; Goran, M.I.; Bosy-Westphal, A.; King, J.C.; Schmidt, L.A.; Schwarz, J.M.; Stice, E.; Sylvestsky, A.C.; Turnbaugh, P.J.; Bray, G.A.; et al. Pathways and mechanisms linking dietary components to cardiometabolic disease: Thinking beyond calories. *Obes. Rev.* **2018**, *19*, 1205–1235. [CrossRef] [PubMed]
8. Kosova, E.C.; Auinger, P.; Bremer, A.A. The relationships between sugar-sweetened beverage intake and cardiometabolic markers in young children. *J. Acad. Nutr. Diet.* 2013, **113**, 219–227. [CrossRef]

9. Bremer, A.A.; Auinger, P.; Byrd, R.S. Relationship between insulin resistance-associated metabolic parameters and anthropometric measures with sugar-sweetened beverage intake and physical activity levels in US adolescents: Findings from the 1999–2004 National Health and Nutrition Examination Survey. *Arch. Pediatr. Adolesc. Med.* 2009, **163**, 328–335. [CrossRef]

10. Cioffi, C.E.; Welsh, J.A.; Alvarez, J.A.; Hartmann, T.J.; Narayan, K.M.V.; Vos, M.B. Associations of Added Sugar from All Sources and Sugar-Sweetened Beverages with Regional Fat Deposition in US Adolescents: NHANES 1999–2006. *Curr. Dev. Nutr.* 2019, **3**, nzz130. [CrossRef]

11. Goree, L.L.; Chandler-Laney, P.; Ellis, A.C.; Casazza, K.; Granger, W.M.; Gower, B.A. Dietary macronutrient composition affects ß cell responsiveness but not insulin sensitivity. *Am. J. Clin. Nutr.* 2011, **94**, 120–127. [CrossRef] [PubMed]

12. Cohen, C.C.; Li, K.W.; Alazraki, A.L.; Beysen, C.; Cleeton, R.L.; Dandan, M.; Figueroa, J.; Knight-Scott, J.; Knott, C.J.; et al. Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease. *J. Clin. Investig.* 2021, **131**, e150996. [CrossRef] [PubMed]

13. Schwarz, J.M.; Noworolski, S.M.; Wen, M.J.; Dyachenko, A.; Prior, J.L.; Weinberg, M.E.; Herraiz, L.A.; Tai, W.V.; Bergeron, N.; Bersot, T.P.; et al. Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat. *J. Endocrinol. Metab.* 2015, **100**, 2434–2442. [CrossRef] [PubMed]

14. Schwarz, J.M.; Noworolski, S.M.; Erkin-Cakmak, A.; Korn, N.J.; Wen, M.J.; Tai, V.W.; Jones, G.M.; Palii, S.P.; Velasco-Alin, M.; Pan, K.; et al. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity. *Gastroenterology* 2017, **153**, 743–752. [CrossRef]

15. Stanhope, K.L.; Schwarz, J.M.; Keim, N.L.; Griffen, S.C.; Bremer, A.A.; Graham, J.L.; Hatcher, B.; Cox, C.L.; Dyachenko, A.; Zhang, W.; et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. *J. Clin. Investig.* 2009, **119**, 1322–1334. [CrossRef]

16. Geidl-Flueck, B.; Hochuli, M.; Németh, A.; Eberl, A.; Derron, N.; Köfeler, H.C.; Tappy, L.; Berneis, K.; Spinas, G.A.; Gerber, P.A. Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. *J. Hepatol.* 2021, **75**, 46–54. [CrossRef]

17. Uppal, K.; Walker, D.I.; Liu, K.; Li, S.; Go, Y.-M.; Jones, D.P. Computational Metabolomics: A Framework for the Million Cell Res. Toxicol. 2016, **29**, 1956–1975. [CrossRef]

18. Gibbons, H.; McNulty, B.A.; Nugent, A.P.; Walton, J.; Flynn, A.; Gibney, M.J.; Brennan, L. A metabolomics approach to the identification of biomarkers of sugar-sweetened beverage intake. *Am. J. Clin. Nutr.* 2015, **101**, 471–477. [CrossRef]

19. Vineis, P.; Perera, F. Molecular Epidemiology and Biomarkers in Etiologic Cancer Research: The New in Light of the Old. *Cancer Epidemiol. Biomark. Prev.* 2007, **16**, 1954–1965. [CrossRef]

20. Perng, W.; Tang, L.; Song, P.X.K.; Goran, M.; Tellez Rojo, M.M.; Cantoral, A.; Peterson, K.E. Urate and Nonanoate Mark the Relationship between Sugar-Sweetened Beverage Intake and Blood Pressure in Adolescent Girls: A Metabolomics Analysis in the ELEMENT Cohort. *Metabolites* 2019, **9**, 100. [CrossRef]

21. Te Morenga, L.A.; Howatson, A.J.; Jones, R.M.; Mann, J. Dietary sugars and cardiometabolic risk: Systematic review and meta-analyses of randomized controlled trials of the effects on blood pressure and lipids. *Am. J. Clin. Nutr.* 2014, **100**, 65–79. [CrossRef] [PubMed]

22. Mayes, P.A. Intermediary metabolism of fructose. *Am. J. Clin. Nutr.* 1993, **58**, 754s–765s. [CrossRef] [PubMed]

23. Schultz, A.; Neil, D.; Aguila, M.B.; Mandarim-de-Lacerda, C.A. Hepatic adverse effects of fructose consumption independent of cell responsiveness but not insulin sensitivity. *Int. J. Mol. Sci.* 2013, **14**, 21873–21886. [CrossRef]

24. Kim, M.-S.; Krawczyk, S.A.; Doridot, L.; Fowler, A.J.; Wang, J.X.; Trauger, S.A.; Noh, H.-L.; Kang, H.J.; Meissen, J.K.; Bhatnag, M.; et al. Fructose- and sucrose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. *J. Clin. Investig.* 2016, **126**, 4372–4386. [CrossRef] [PubMed]

25. Cox, C.L.; Stanhope, K.L.; Schwarz, J.M.; Graham, J.L.; Hatcher, B.; Griffen, S.C.; Bremer, A.A.; Berglund, L.; McGahan, J.P.; Havel, P.J.; et al. Consumption of fructose-sweetened beverages for 10 weeks reduces net fat oxidation and energy expenditure in overweight/obese men and women. *Am. J. Clin. Nutr.* 2012, **96**, 201–208. [CrossRef]

26. Maersk, M.; Belza, A.; Stædkilde-Jørgensen, H.; Ringgaard, S.; Chabanova, E.; Thomsen, H.; Pedersen, S.B.; Astrup, A.; Richelsen, B. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: A 6-mo randomized intervention study. *Am. J. Clin. Nutr.* 2011, **95**, 283–289. [CrossRef]

27. Stapleton, P.P.; Charles, R.P.; Redmond, H.P.; Bouchier-Hayes, D.J. Taurine and human nutrition. *Clin. Nutr.* 1997, **16**, 103–108. [CrossRef]

28. Mingrone, G.; Castagneto-Gissey, L.; Macé, K. Use of dicarboxylic acids in type 2 diabetes. *Br. J. Clin. Pharm.* 2013, **75**, 671–676. [CrossRef]

29. Butte, N.F.; Liu, Y.; Zakeri, I.F.; Mohney, R.P.; Mehta, N.; Voruganti, V.S.; Göring, H.; Cole, S.A.; Comuzzie, A.G. Global metabolomic profiling targeting childhood obesity in the Hispanic population. *Am. J. Clin. Nutr.* 2015, **102**, 256–267. [CrossRef]

30. Roglans, N.; Vilà, L.; Farré, M.; Alegret, M.; Sánchez, R.M.; Vázquez-Carrera, M.; Laguna, J.C. Impairment of hepatic Stat-3 activation and reduction of PPARα activity in fructose-fed rats. *Hepatology* 2007, **45**, 778–788. [CrossRef]
31. Razquin, C.; Liang, L.; Toledo, E.; Clish, C.B.; Ruiz-Canela, M.; Zheng, Y.; Wang, D.D.; Corella, D.; Castaner, O.; Ros, E.; et al. Plasma lipidome patterns associated with cardiovascular risk in the PREDIMED trial: A case-cohort study. *Int. J. Cardiol.* **2018**, *253*, 126–132. [CrossRef] [PubMed]

32. Wang, D.D.; Zheng, Y.; Toledo, E.; Razquin, C.; Ruiz-Canela, M.; Guasch-Ferré, M.; Yu, E.; Corella, D.; Gómez-Gracia, E.; Fiol, M.; et al. Lipid metabolic networks, Mediterranean diet and cardiovascular disease in the PREDIMED trial. *Int. J. Epidemiol.* **2018**, *47*, 1830–1845. [CrossRef] [PubMed]

33. Koves, T.R.; Usher, J.R.; Noland, R.C.; Slentz, D.; Mosedale, M.; Ilkayeva, O.; Bain, J.; Stevens, R.; Dyck, J.R.; Newgard, C.B.; et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. *Cell Metab.* **2008**, *7*, 45–56. [CrossRef] [PubMed]

34. Razquin, C.; Toledo, E.; Clish, C.B.; Ruiz-Canela, M.; Dennis, C.; Corella, D.; Papandreou, C.; Ros, E.; Estruch, R.; Guasch-Ferré, M.; et al. Plasma Lipidomic Profiling and Risk of Type 2 Diabetes in the PREDIMED Trial. *Diabetes Care* **2018**, *41*, 2617–2624. [CrossRef]

35. Guasch-Ferré, M.; Hruby, A.; Toledo, E.; Clish, C.B.; Martínez-González, M.A.; Salas-Salvadó, J.; Hu, F.B. Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis. *Diabetes Care* **2016**, *39*, 833–846. [CrossRef] [PubMed]

36. McGaraghan, P.; Kirwan, J.A.; Garcia-Rivera, M.A.; Pieske, B.; Edelmann, F.; Blaschke, F.; Appunni, S.; Saxena, A.; Rubens, M.; Veledar, E.; et al. Lipid Metabolite Biomarkers in Cardiovascular Disease: Discovery and Biomechanism Translation from Human Studies. *Metabolites* **2021**, *11*, 621. [CrossRef]

37. Papandreou, C.; Harrold, J.A.; Hansen, T.T.; Halford, J.C.G.; Sjödin, A.; Bulló, M. Changes in Circulating Metabolites during Weight Loss and Weight Loss Maintenance in Relation to Cardiometabolic Risk. *Nutrients* **2021**, *13*, 4289. [CrossRef] [PubMed]

38. Quinn, W.J., 3rd; Wan, M.; Shewale, S.V.; Gelfer, R.; Rader, D.J.; Birnbaum, M.; Titchenell, P.M. mTORC1 stimulates phosphatidylcholine synthesis to promote triglyceride secretion. *J. Clin. Investig.* **2017**, *127*, 4207–4215. [CrossRef]

39. Wehling, H.; Lusher, J. People with a body mass index ≥30 under-report their dietary intake: A systematic review. *J. Health Psychol.* **2019**, *24*, 2042–2059. [CrossRef]

40. Willett, W.; Stampfer, M.J. Total energy intake: Implications for epidemiologic analyses. *Am. J. Epidemiol.* **1986**, *124*, 17–27. [CrossRef]

41. Guevara, R.M.; Moral-García, J.E.; Urchaga, J.D.; López-García, S. Relevant Factors in Adolescent Well-Being: Family and Parental Relationships. *Int. J. Environ. Res. Public Health* **2021**, *18*, 7666. [CrossRef] [PubMed]

42. Eck, K.M.; Dinesen, A.; Garcia, E.; Delaney, C.L.; Famodu, O.A.; Olfert, M.D.; Byrd-Bredbenner, C.; Shelnutt, K.P. “Your Body Feels Better When You Drink Water”: Parent and School-Age Children’s Sugar-Sweetened Beverage Cognitions. *Int. J. Environ. Res. Public Health* **2021**, *18*, 4207–4219. [CrossRef]

43. Godin, K.M.; Chaurasia, A.; Hammond, D.; Leatherdale, S.T. Examining associations between school food environment characteristics and sugar-sweetened beverage consumption among Canadian secondary-school students in the COMPASS study. *Public Health Nutr.* **2019**, *22*, 1928–1940. [CrossRef]

44. Crume, T.L.; Ogden, L.; West, N.A.; Vehik, K.S.; Scherzinger, A.; Daniels, S.; McDuffie, R.; Bischoff, K.; Hamman, R.F.; Norris, J.M.; et al. Association of exposure to diabetes in utero with adiposity and fat distribution in a multietnic population of youth: The Exploring Perinatal Outcomes among Children (EPOCH) Study. *Diabetologia* **2011**, *54*, 87–92. [CrossRef] [PubMed]

45. Mayer-Davis, E.J.; Nichols, M.; Liee, A.D.; Bell, R.A.; Dabelea, D.M.; Johansen, J.M.; Pihoker, C.; Rodriguez, B.L.; Thomas, J.; Williams, D. Dietary intake among youth with diabetes: The SEARCH for Diabetes in Youth Study. *J. Am. Diet. Assoc.* **2006**, *106*, 689–697. [CrossRef] [PubMed]

46. Cullen, K.W.; Watson, K.; Zakeri, I. Relative reliability and validity of the Block Kids Questionnaire among youth aged 10 to 17 years. *J. Am. Diet. Assoc.* **2008**, *108*, 862–866. [CrossRef] [PubMed]

47. Block, G.; Murphy, M.; Roulet, J.B.; Wakimoto, P.; Crawford, P.B.; Block, T. Pilot validation of a FFQ for children 8–10 years. In *Weight Loss and Weight Loss Maintenance in Relation to Cardiometabolic Risk*. *Am. J. Epidemiol.* **2014**, *180*, 1928–1940. [CrossRef]

48. Willett, W.C.; Howe, G.R.; Kushi, L.H. Adjustment for total energy intake in epidemiologic studies. *Am. J. Epidemiol.* **1986**, *124*, 17–27. [CrossRef] [PubMed]

49. Perng, W.; Ringham, B.M.; Smith, H.A.; Michelotti, G.; Ke charming, K.M.; Dabelea, D. A prospective study of associations between in utero exposure to gestational diabetes mellitus and metabolic profiles during late childhood and adolescence. *Diabetologia* **2020**, *63*, 296–312. [CrossRef]

50. Perng, W.; Francis, E.C.; Smith, H.A.; Carey, J.; Wang, D.; Kecharis, K.M.; Dabelea, D. Sex-Specific Metabolite Biomarkers of NAFLD in Youth: A Prospective Study in the EPOCH Cohort. *J. Clin. Endocrinol. Metab.* **2020**, *105*, e3437–e3450. [CrossRef]

51. Schiffman, C.; Petrick, L.; Perttula, K.; Yano, Y.; Carlsson, H.; Whitehead, T.; Metayer, C.; Hayes, J.; Rappaport, S.; Dudoit, S. Filtering procedures for untargeted LC-MS metabolomics data. *BMC Bioinform.* **2019**, *20*, 334. [CrossRef]

52. Riso, D.; Nga, J.; Speed, T.P.; Dudoit, S. Normalization of RNA-seq data using factor analysis of control genes or samples. *Nat. Biotechnol.* **2014**, *32*, 896–902. [CrossRef] [PubMed]

53. R Development Core Team. *R: A Language Environment for Statistical Computing*; R Foundation for Statistical Computing: Vienna, Austria, 2021; Available online: [https://www.R-project.org/](https://www.R-project.org/) (accessed on 11 April 2022).
54. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* **1985**, *28*, 412–419. [CrossRef] [PubMed]

55. Classification and Diagnosis of Diabetes. *Diabetes Care* **2017**, *40*, S11–S24. [CrossRef] [PubMed]

56. de Onis, M.; Onyango, A.W.; Borghi, E.; Siyam, A.; Nishida, C.; Siekmann, J. Development of a WHO growth reference for school-aged children and adolescents. *Bull. World Health Organ.* **2007**, *85*, 660–667. [CrossRef] [PubMed]

57. Chavarro, J.E.; Watkins, D.J.; Afeiche, M.C.; Zhang, Z.; Sánchez, B.N.; Cantonwine, D.; Mercado-García, A.; Blank-Goldenberg, C.; Meeker, J.D.; Téllez-Rojo, M.M.; et al. Validity of Self-Assessed Sexual Maturation Against Physician Assessments and Hormone Levels. *J. Pediatr.* **2017**, *186*, 172–178.e173. [CrossRef]

58. Tibshirani, R. Regression shrinkage and selection via the lasso. *J. R. Stat. Soc. Ser. B* **1996**, *58*, 267–288. [CrossRef]

59. Reinehr, T.; Wolters, B.; Knop, C.; Lass, N.; Holl, R.W. Strong Effect of Pubertal Status on Metabolic Health in Obese Children: A Longitudinal Study. *J. Clin. Endocrinol. Metab.* **2015**, *100*, 301–308. [CrossRef]